مؤتمر
Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial
| العنوان: | Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial |
|---|---|
| المؤلفون: | Armstrong, A. J., Clarke, Noel W, Thiery-Vuillemin, A., Oya, M., Procopio, G., De Menezes, J. J., Girotto, G. C., Ghatalia, P., Din, F. N. O., Spiegelhalder, P., Mincik, I., Van Alphen, R. J., Lumen, N., Hosius, C., Zhou, D. S., Barker, L., Dujka, M. E., Saad, F. |
| المساهمون: | Duke University Medical Center, Durham, NC |
| سنة النشر: | 2022 |
| المجموعة: | The Christie School of Oncology: Christie Research Publications Repository |
| نوع الوثيقة: | conference object |
| اللغة: | English |
| العلاقة: | https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5050Test; Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301470.; http://hdl.handle.net/10541/625805Test; Journal of Clinical Oncology |
| DOI: | 10.1200/JCO.2022.40.16_suppl.5050 |
| الإتاحة: | https://doi.org/10.1200/JCO.2022.40.16_suppl.5050Test http://hdl.handle.net/10541/625805Test |
| رقم الانضمام: | edsbas.AC120190 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/JCO.2022.40.16_suppl.5050 |
|---|